|
Market Cap | 2.76B | EPS (ttm) | -0.50 |
P/E | - | EPS this Y | 58.66% |
Forward P/E | 42.43 | EPS next Y | 204.28% |
PEG | - | EPS past 5Y | 22.84% |
P/S | 6.53 | EPS next 5Y | - |
P/B | 21.14 | EPS Q/Q | 12.05% |
Dividend | - | Sales Q/Q | 27.97% |
Insider Own | 2.84% | Inst Own | 106.43% |
Insider Trans | -5.70% | Inst Trans | -4.32% |
Short Float | 10.00% | Earnings | May 09/b |
Analyst Recom | 1.36 | Target Price | 17.50 |
Avg Volume | 3.10M | 52W Range | 9.02 - 14.57 |
|
|
May-14-24 | Upgrade |
Guggenheim |
Neutral → Buy |
$13 |
|
|
Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Campbell Bradley L | President and CEO | May 01 '24 | Option Exercise | 8.61 | 7,500 | 64,575 | 894,154 | May 03 05:21 PM | Campbell Bradley L | President and CEO | May 01 '24 | Sale | 10.07 | 7,500 | 75,524 | 886,654 | May 03 05:21 PM | Campbell Bradley L | President and CEO | Apr 01 '24 | Option Exercise | 8.61 | 7,500 | 64,575 | 894,154 | Apr 03 06:14 PM | Campbell Bradley L | President and CEO | Apr 01 '24 | Sale | 11.67 | 7,500 | 87,496 | 886,654 | Apr 03 06:14 PM | SBLENDORIO GLENN | Director | Mar 07 '24 | Option Exercise | 2.80 | 15,000 | 42,000 | 83,596 | Mar 11 05:36 PM |
|
|
|
|
Market Cap | 17.69B | EPS (ttm) | 6.67 |
P/E | 17.58 | EPS this Y | 9.15% |
Forward P/E | 16.62 | EPS next Y | 5.94% |
PEG | 2.34 | EPS past 5Y | 2.36% |
P/S | 4.36 | EPS next 5Y | 7.50% |
P/B | 1.52 | EPS Q/Q | 14.95% |
Dividend | 2.75% | Sales Q/Q | 6.90% |
Insider Own | 0.35% | Inst Own | 95.04% |
Insider Trans | -3.07% | Inst Trans | 1.69% |
Short Float | 2.54% | Earnings | May 08/a |
Analyst Recom | 2.20 | Target Price | 128.50 |
Avg Volume | 875.12K | 52W Range | 101.00 - 125.28 |
|
|
May-14-24 | Upgrade |
Wells Fargo |
Equal Weight → Overweight |
$130 → $132 |
|
|
Atmos Energy Corp. engages in the provision of natural gas services. It operates through the Distribution, and Pipeline and Storage segments. The Distribution segment is involved in regulated natural gas distribution and related sales operations. The Pipeline and Storage segment includes pipeline and storage operations of the Atmos Pipeline-Texas division and natural gas transmission operations. The company was founded in 1983 and is headquartered in Dallas, TX. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
AKERS JOHN K | PRESIDENT & CEO | May 03 '24 | Option Exercise | 119.09 | 14,290 | 1,701,796 | 91,672 | May 06 05:09 PM | Forsythe Christopher T | SR VICE PRESIDENT & CFO | May 03 '24 | Option Exercise | 119.09 | 4,400 | 523,996 | 50,842 | May 06 05:16 PM | HARTSFIELD KAREN E | SR VP, GC & CORPORATE SEC'Y | May 03 '24 | Option Exercise | 119.09 | 3,215 | 382,874 | 24,904 | May 06 05:17 PM | ROBBINS J MATT | SR VP, HUMAN RESOURCES | May 03 '24 | Option Exercise | 119.09 | 3,215 | 382,874 | 22,306 | May 06 05:21 PM | MCDILL JOHN S | SR VP, UTILITY OPERATIONS | May 03 '24 | Option Exercise | 119.09 | 1,600 | 190,544 | 27,538 | May 06 05:20 PM |
|
|
|
|
Market Cap | 52.10B | EPS (ttm) | 2.33 |
P/E | 37.16 | EPS this Y | 10.43% |
Forward P/E | 27.77 | EPS next Y | 12.34% |
PEG | 3.94 | EPS past 5Y | 15.35% |
P/S | 8.48 | EPS next 5Y | 9.44% |
P/B | 7.32 | EPS Q/Q | 4.50% |
Dividend | - | Sales Q/Q | 9.50% |
Insider Own | 1.61% | Inst Own | 83.23% |
Insider Trans | -4.18% | Inst Trans | -0.08% |
Short Float | 1.62% | Earnings | Apr 25/a |
Analyst Recom | 2.03 | Target Price | 96.55 |
Avg Volume | 3.38M | 52W Range | 60.57 - 96.12 |
|
|
May-14-24 | Upgrade |
Deutsche Bank |
Hold → Buy |
|
|
|
Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
BOBO DONALD E JR | CVP,Strategy/Corp Development | May 10 '24 | Option Exercise | 45.28 | 5,000 | 226,384 | 52,750 | May 13 05:45 PM | BOBO DONALD E JR | CVP,Strategy/Corp Development | May 10 '24 | Sale | 87.81 | 5,000 | 439,038 | 47,750 | May 13 05:45 PM | Lippis Daniel J. | CVP, JAPAC | May 07 '24 | Option Exercise | 36.75 | 857 | 31,495 | 25,333 | May 09 07:40 PM | Lippis Daniel J. | CVP, JAPAC | May 07 '24 | Sale | 85.60 | 857 | 73,359 | 23,890 | May 09 07:40 PM | Zovighian Bernard J | CEO | May 06 '24 | Buy | 85.74 | 580 | 49,753 | 3,268 | May 07 05:53 PM |
|
|
| |
|
Market Cap | 453.45M | EPS (ttm) | -1.67 |
P/E | - | EPS this Y | 19.64% |
Forward P/E | 25.97 | EPS next Y | 32.24% |
PEG | - | EPS past 5Y | - |
P/S | 0.43 | EPS next 5Y | - |
P/B | 0.68 | EPS Q/Q | -92.58% |
Dividend | - | Sales Q/Q | -1.02% |
Insider Own | 12.24% | Inst Own | 101.84% |
Insider Trans | 0.15% | Inst Trans | - |
Short Float | 6.95% | Earnings | May 08/a |
Analyst Recom | 3.12 | Target Price | 9.32 |
Avg Volume | 632.49K | 52W Range | 7.12 - 14.59 |
|
|
May-14-24 | Upgrade |
Leerink Partners |
Underperform → Market Perform |
$8.50 |
|
May-14-24 07:54AM
|
Leerink Partners Upgrades Enhabit to Market Perform From Underperform, Price Target is $8.50
(MT Newswires) |
May-10-24 03:01PM
|
Enhabit Inc (EHAB) Reports Mixed Q1 2024 Results: Challenges and Strategic Adjustments Highlighted
(GuruFocus.com) |
11:24AM
|
UBS Trims Price Target on Enhabit to $9 From $10, Keeps Neutral Rating
(MT Newswires) |
May-09-24 01:47PM
|
Hedge Fund and Insider Trading News: John Paulson, Ken Griffin, Marshall Wace LLP, Bridgewater Associates, AREX Capital Management, Ancora Advisors, Millennium Management, Balyasny Asset Management, Caesars Entertainment Inc (CZR), Vestis Corporation (VSTS), and More
(Insider Monkey) -14.54% |
09:15AM
|
AREX Capital Expresses Disappointment in Enhabit's Strategic Review Conclusion
(GlobeNewswire) |
07:13AM
|
Jefferies Downgrades Enhabit to Hold From Buy, Price Target at $8.75
(MT Newswires) |
May-08-24 06:55PM
|
Enhabit (EHAB) Beats Q1 Earnings Estimates
(Zacks) |
05:48PM
|
Enhabit: Q1 Earnings Snapshot
(Associated Press Finance) |
04:15PM
|
Enhabit Concludes Review of Strategic Alternatives
(Business Wire) |
04:10PM
|
Enhabit Reports First Quarter 2024 Financial Results
(Business Wire) |
|
Enhabit, Inc. functions as an investment holding company. It operates under the Home Health and Hospice segments. The Home Health segment provides home health services via home nursing services to adult patients in need of care. The Hospice segment offers hospice agencies. The company was founded in 2014 and is headquartered in Dallas, TX. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Bolton Jeffrey | Director | May 10 '24 | Buy | 8.24 | 10,000 | 82,400 | 42,299 | May 10 05:27 PM | Langham Ronald Leroy JR | EVP Clinical Excel. & Strategy | Mar 01 '24 | Sale | 8.81 | 634 | 5,586 | 57,164 | Mar 05 05:48 PM | Bolton Jeffrey | Director | May 26 '23 | Buy | 11.61 | 2,000 | 23,220 | 19,597 | May 31 08:17 PM | SHAW L EDWARD JR | Director | May 22 '23 | Buy | 11.98 | 10,000 | 119,800 | 38,989 | May 23 05:50 PM | Langham Ronald Leroy JR | EVP Clinical Excel. & Strategy | May 18 '23 | Buy | 11.99 | 10,000 | 119,900 | 44,328 | May 22 09:48 AM |
|
|
|
|
Market Cap | 16.60B | EPS (ttm) | 4.72 |
P/E | 24.91 | EPS this Y | -3.51% |
Forward P/E | 22.80 | EPS next Y | 6.61% |
PEG | - | EPS past 5Y | 7.60% |
P/S | 1.86 | EPS next 5Y | - |
P/B | 7.55 | EPS Q/Q | -19.27% |
Dividend | 1.34% | Sales Q/Q | -14.89% |
Insider Own | 0.71% | Inst Own | 99.97% |
Insider Trans | -0.60% | Inst Trans | 0.02% |
Short Float | 4.71% | Earnings | May 07/b |
Analyst Recom | 3.76 | Target Price | 109.50 |
Avg Volume | 1.30M | 52W Range | 107.03 - 131.17 |
|
|
May-14-24 | Upgrade |
Exane BNP Paribas |
Underperform → Neutral |
$112 |
|
|
Expeditors International of Washington, Inc. engages in the provision of global logistics services. The firm offers air freight, ocean freight and ocean and customs brokerage and other services. It also provides customer solutions such as order management, time-definite transportation, warehousing and distribution, temperature-controlled transit, cargo insurance and customized logistics solutions. The company was founded by John M. Kaiser, Peter Rose, Wang Li Kou, Kevin Walsh, Hank Wong, George Ho, Robert Chiarito, and Glenn Alger in 1979 and is headquartered in Seattle, WA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Bell Blake R | President, Global Services | May 08 '24 | Sale | 116.99 | 4,100 | 479,659 | 52,745 | May 10 01:48 PM | Bell Blake R | President, Global Services | May 03 '24 | Option Exercise | 0.00 | 1,323 | 0 | 57,093 | May 07 03:39 PM | Blacker Kelly K | President, Global Products | May 03 '24 | Option Exercise | 0.00 | 1,653 | 0 | 8,076 | May 07 03:43 PM | Clark Benjamin G. | SVP - Chief Strategy Officer | May 03 '24 | Option Exercise | 0.00 | 1,653 | 0 | 20,994 | May 07 03:47 PM | Dickerman Jeffrey F | Senior VP/Gen Counsel/Corp Sec | May 03 '24 | Option Exercise | 0.00 | 1,653 | 0 | 7,508 | May 07 03:51 PM |
|
|
| |
|
Market Cap | 2.32B | EPS (ttm) | -0.18 |
P/E | - | EPS this Y | 498.81% |
Forward P/E | 16.15 | EPS next Y | 55.22% |
PEG | - | EPS past 5Y | 38.49% |
P/S | 1.49 | EPS next 5Y | - |
P/B | 1.77 | EPS Q/Q | 58.32% |
Dividend | - | Sales Q/Q | 13.03% |
Insider Own | 4.45% | Inst Own | 89.28% |
Insider Trans | 0.00% | Inst Trans | 5.22% |
Short Float | 5.99% | Earnings | Apr 25/b |
Analyst Recom | 1.67 | Target Price | 24.83 |
Avg Volume | 814.72K | 52W Range | 14.33 - 25.04 |
|
|
May-14-24 | Upgrade |
Barclays |
Equal Weight → Overweight |
$18 → $27 |
|
|
Expro Group Holdings NV engages in the provision of energy services. It operates through the following geographical segments: North and Latin America (NLA), Europe and Sub-Saharan Africa (ESSA), Middle East and North Africa (MENA), and Asia-Pacific (APAC). The company was founded in 1938 and is headquartered in Houston, TX. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
KEARNEY MICHAEL C | Director | Sep 15 '23 | Sale | 24.16 | 15,400 | 372,093 | 27,633 | Sep 15 04:05 PM | Drummond Robert Wayne Jr | Director | Sep 15 '23 | Sale | 24.19 | 13,000 | 314,516 | 43,433 | Sep 15 04:07 PM | OAK HILL ADVISORS LP | 10% Owner | Sep 14 '23 | Sale | 22.95 | 3,000,000 | 68,865,000 | 14,575,891 | Sep 18 04:05 PM | KEARNEY MICHAEL C | Director | Sep 13 '23 | Sale | 23.84 | 2,600 | 61,984 | 43,033 | Sep 13 05:13 PM | KEARNEY MICHAEL C | Director | Sep 06 '23 | Sale | 24.44 | 5,735 | 140,157 | 45,633 | Sep 07 04:54 PM |
|
|
|
|
Market Cap | 12.54B | EPS (ttm) | 0.07 |
P/E | 1994.89 | EPS this Y | 156.76% |
Forward P/E | 13.28 | EPS next Y | 203.34% |
PEG | - | EPS past 5Y | -1.21% |
P/S | 8.94 | EPS next 5Y | - |
P/B | 13.04 | EPS Q/Q | 106.22% |
Dividend | - | Sales Q/Q | 63.10% |
Insider Own | 5.86% | Inst Own | 85.56% |
Insider Trans | -0.50% | Inst Trans | 6.35% |
Short Float | 6.40% | Earnings | May 01/a |
Analyst Recom | 1.38 | Target Price | 168.30 |
Avg Volume | 922.49K | 52W Range | 55.25 - 159.89 |
|
|
May-14-24 | Upgrade |
Oppenheimer |
Perform → Outperform |
$180 |
|
|
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Murray Dallan | Chief Customer Officer | May 02 '24 | Sale | 140.00 | 3,635 | 508,900 | 18,125 | May 06 08:09 PM | Boor Kathryn Jean | Director | Mar 11 '24 | Sale | 122.93 | 761 | 93,550 | 7,516 | Mar 11 08:00 PM | Wigzell Hans Lennart Rudolf | Director | Mar 08 '24 | Option Exercise | 13.90 | 15,000 | 208,500 | 37,840 | Mar 11 08:02 PM | Wigzell Hans Lennart Rudolf | Director | Mar 08 '24 | Sale | 123.25 | 15,000 | 1,848,795 | 22,840 | Mar 11 08:02 PM | Mayo Stephen | Director | Mar 05 '24 | Sale | 122.96 | 3,135 | 385,480 | 6,621 | Mar 06 08:00 PM |
|
|
| |
|
Market Cap | 1.35B | EPS (ttm) | 0.00 |
P/E | - | EPS this Y | 124.04% |
Forward P/E | 46.96 | EPS next Y | 788.11% |
PEG | - | EPS past 5Y | 76.52% |
P/S | 6.37 | EPS next 5Y | - |
P/B | 5.55 | EPS Q/Q | - |
Dividend | - | Sales Q/Q | 24.52% |
Insider Own | 72.26% | Inst Own | 17.58% |
Insider Trans | 0.00% | Inst Trans | -7.17% |
Short Float | 0.27% | Earnings | May 07/a |
Analyst Recom | 1.29 | Target Price | 10.33 |
Avg Volume | 547.05K | 52W Range | 3.76 - 9.59 |
|
|
May-14-24 | Upgrade |
JP Morgan |
Neutral → Overweight |
$9 |
|
|
VTEX provides software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables its customers to execute its commerce strategy, including building online stores, integrating and managing orders across channels, and creating marketplaces to sell products from third- party vendors. The company was founded by Geraldo do Carmo Thomaz Junior and Mariano Gomide de Faria in 2000 and is headquartered in London, the United Kingdom. |
|
|